PNH diagnosis consists of recognizing the symptoms patients exhibit and testing to confirm PNH diagnosis
aDetects PNH cells down to a 0.01% clone size.
LDH ≥1.5 x ULN has been shown to significantly increase the risk for thrombosis and be a predictor of premature mortality in patients with PNH.11,12,b,c
bA retrospective chart review of 301 patients with PNH, enrolled into the South Korean PNH registry, assessed the clinical signs and symptoms predictive of mortality using a standardized mortality ratio compared with an age- and sex-matched general Korean population.12
cA retrospective analysis of 301 patients from the South Korean PNH registry evaluated risk factors for thrombosis using a multivariate analysis matched for age, sex, and bone marrow failure. Data are presented as odds ratios comparing patients with LDH ≥1.5 x ULN with specified symptoms to patients with LDH <1.5 x ULN and no symptoms.11
Regularly assess for labs indicating hemolysis along with clinical signs and symptoms to help diagnose PNH. Once positive for PNH, monitor LDH as it is an indicator of intravascular hemolysis associated with risk for thrombosis, organ damage, and early mortality in PNH3,10-12
ACD=adenosine, citrate, dextrose; EDTA=ethylenediaminetetraacetic acid; FLAER=fluorescent aerolysin; GPI=glycosylphosphatidylinositol; ICCS=International Clinical Cytometry Society; IPIG=International PNH Interest Group; LDH=lactate dehydrogenase; PNH=paroxysmal nocturnal hemoglobinuria; ULN=upper limit of normal.